C4 Therapeutics Statistics
Total Valuation
C4 Therapeutics has a market cap or net worth of $455.54 million. The enterprise value is $245.71 million.
| Market Cap | 455.54M |
| Enterprise Value | 245.71M |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
C4 Therapeutics has 110.57 million shares outstanding. The number of shares has increased by 38.20% in one year.
| Current Share Class | 110.57M |
| Shares Outstanding | 110.57M |
| Shares Change (YoY) | +38.20% |
| Shares Change (QoQ) | +7.96% |
| Owned by Insiders (%) | 1.13% |
| Owned by Institutions (%) | 71.40% |
| Float | 83.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.07 |
| Forward PS | 28.15 |
| PB Ratio | 1.83 |
| P/TBV Ratio | 1.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.00, with a Debt / Equity ratio of 0.25.
| Current Ratio | 9.00 |
| Quick Ratio | 8.75 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -48.35% and return on invested capital (ROIC) is -23.34%.
| Return on Equity (ROE) | -48.35% |
| Return on Assets (ROA) | -19.88% |
| Return on Invested Capital (ROIC) | -23.34% |
| Return on Capital Employed (ROCE) | -34.19% |
| Weighted Average Cost of Capital (WACC) | 18.04% |
| Revenue Per Employee | $335,202 |
| Profits Per Employee | -$998,087 |
| Employee Count | 104 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, C4 Therapeutics has paid $121,000 in taxes.
| Income Tax | 121,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +190.14% in the last 52 weeks. The beta is 2.93, so C4 Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 2.93 |
| 52-Week Price Change | +190.14% |
| 50-Day Moving Average | 3.38 |
| 200-Day Moving Average | 2.67 |
| Relative Strength Index (RSI) | 60.46 |
| Average Volume (20 Days) | 2,441,033 |
Short Selling Information
The latest short interest is 21.65 million, so 19.58% of the outstanding shares have been sold short.
| Short Interest | 21.65M |
| Short Previous Month | 21.25M |
| Short % of Shares Out | 19.58% |
| Short % of Float | 25.86% |
| Short Ratio (days to cover) | 7.25 |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of $34.86 million and -$103.80 million in losses. Loss per share was -$1.07.
| Revenue | 34.86M |
| Gross Profit | 27.31M |
| Operating Income | -103.11M |
| Pretax Income | -103.68M |
| Net Income | -103.80M |
| EBITDA | -101.20M |
| EBIT | -103.11M |
| Loss Per Share | -$1.07 |
Balance Sheet
The company has $235.67 million in cash and $58.45 million in debt, with a net cash position of $209.82 million or $1.90 per share.
| Cash & Cash Equivalents | 235.67M |
| Total Debt | 58.45M |
| Net Cash | 209.82M |
| Net Cash Per Share | $1.90 |
| Equity (Book Value) | 234.25M |
| Book Value Per Share | 2.25 |
| Working Capital | 218.12M |
Cash Flow
In the last 12 months, operating cash flow was -$95.35 million and capital expenditures -$671,000, giving a free cash flow of -$96.02 million.
| Operating Cash Flow | -95.35M |
| Capital Expenditures | -671,000 |
| Depreciation & Amortization | 1.91M |
| Net Borrowing | n/a |
| Free Cash Flow | -96.02M |
| FCF Per Share | -$0.87 |
Margins
Gross margin is 78.34%, with operating and profit margins of -295.77% and -297.76%.
| Gross Margin | 78.34% |
| Operating Margin | -295.77% |
| Pretax Margin | -297.41% |
| Profit Margin | -297.76% |
| EBITDA Margin | -290.30% |
| EBIT Margin | -295.77% |
| FCF Margin | n/a |
Dividends & Yields
C4 Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.20% |
| Shareholder Yield | -38.20% |
| Earnings Yield | -22.79% |
| FCF Yield | -21.08% |
Analyst Forecast
The average price target for C4 Therapeutics is $13.33, which is 223.54% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.33 |
| Price Target Difference | 223.54% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -22.18% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
C4 Therapeutics has an Altman Z-Score of -2.24 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.24 |
| Piotroski F-Score | 2 |